BACKGROUND AND PURPOSE: Stroke remains the third most common cause of death in industrialized nations, and the single most common reason for permanent disability. Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA, Alteplase) for the treatment of acute ischemic stroke within 3 hours of onset become, a worldwide conventional standard of care. Thrombolytic stroke therapy is based on the "recanalization hypothesis," that reopening of occluded vessels improves clinical outcome in acute ischemic stroke through regional reperfusion and salvage of threatened tissues. However, intravenous thrombolysis is successful in approximately one third of patients. Thromboaspiration through either a microcatheter, or a guiding catheter may be an option for a fresh nonadhesive clot. The use of mechanical thrombectomy devices in patients experiencing ischemic stroke and reoclusion after intravenous thrombolysis can now gain approval on the basis of recanalization.
CASE DESCRIPTION: We describe a case of a 51-year-old man who presented with ischemic stroke (right-sided hemiparesis and sensomotor aphasia) and sudden onset on 06.50h. He was hospitalised in Neuro intensive Care Unit on 08.10h with NIHSS 8 points. The CT of the head was normal and on 8.40h. began an intravenous rtPa by protocol: body weight 70 kg x 0,9 mg rtPA- 63 mg ACTILYSE with 10% bolus and i.v. infusion for 60 min. After beginning it was a significant improvement with neurological deficite NIHSS 5 points. After the end of the fibrinolysis the patient was with severe deterioration of the symtoms (right-sided hemiplegia and aphasia) - NIHSS 15 points. The patient underwent control CT of the head to exclude intracerebral haemorrhage - was normal. On the digital subtraction angiography there was total thrombosis of the left internal carotid artery. Through a guiding catheter was done thrombo aspiration with effective reperfusion with reversal of neurological deficits - NIHSS 3 points.
CONCLUSIONS: This case represents a valuable example of two recanalization therapies in acute ischemic stroke to improve clinical outcome by restoring anterograde perfusion and salvaging ischemic brain.
Tитянова E. Лечение на острия исхемичен мозъчен инсулт с тромболиза - проблеми и перспективи. В: Четвърта среща на българската асоциация по невросонография и мозъчна хемодинамика с международно участие, 3-4 октомври 2009, София. Невросонография и мозъчна хемодинамика 5, 2009, 2: 122-123.
Adams HP, del Zoppo G, Alberts MJ. ASA Recommendations. Circulation 94, 1996: 1167-1174.
Chapot R, Houdart E, Rogopoulos A, et al. Thromboaspiration in the basilar arter report of two cases. AJNR Am J Neuroradiol 2002;23:282-284.
Clark WM, Wissman S, Albers G. Intravenous rt-PA for acute ischemic stroke beyond 3-hours. (ATLANTIS). JAMA 282, 1999: 2019-2026.
De Silva DA, Brekenfeld C, Ebinger M, Christensen S, Barber PA, Butcher KS, Levi CR, Parsons MW, Bladin CF, Donnan GA, Davis SM: The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke. 2010, 41:295-299
European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee. Guidelines for Management of Ischemic Stroke and Transient Ischemic Attack. 2008.
Fisher M. Characterizing the target of acute stroke treatment. Stroke 28, 1997: 866-872.
Hacke W. Intravenous thrombolysis with recombinant tissue plasminogen activator. (ECASSI) JAMA 274, 1995: 1017-1025.
Hacke W. Randomized double blind placebo con-trolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Lancet 352 (9136), 1998: 1245-1251.
Karolinska Institute, Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke. Lancet 372 (9646), 2008: 1303-1309.
Khatri P, Neff J, Broderick JP, Khoury JC, Carrozzella J, Tomsick T: Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke. 2005, 36:2400-2403.
Kolominsky R. Stroke Morbidity and Mortality in Europe ZAllgMed 78, 2002: 494-500.
International Stroke Trial (IST) A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 349, 1997: 1569-1581.
Menon BK, Hill MD, Eesa M, Modi J, Bhatia R, Wong J, Hudon ME, Morrish W, Demchuk AM, Goyal M: Initial experience with the Penumbra Stroke System for recanalization of large vessel occlusions in acute ischemic stroke. Neuroradiology. 2010, [Epub ahead of print]
Multicenter Acute Stroke Trial-Europe (MAST-E Investigators). Thrombolytic therapy in acute ischemic stroke. N Engl JMed 335, 1996: 145-150.
Multicentre Acute Stroke Trial-Italy (MAST-I Investigators). Thrombolytic therapy with streptokinase in acute ischemic stroke. Lancet 346, 1995: 1509-1514.
NINDS Investigators - Donnan J, Davis S, Kaste M. Efficacy of tissue plasminogen activator for stroke. N Engl JMed 333, 1995: 1581-1587.
Powles J, Kirov Ph, Feschieva N, Stanoev M, Atanasova V. Stroke in urban and rural populations in north-east Bulgaria: incidence and case fatality findings from a'hot pursuit' study. BioMed Central Journal 3, 2002: 65-72.
Schellinger P, Hacke W, Fiebach J. Thrombolysis with Alteplase 3 to 4.5 hours after acute stroke. (ECASSIII) N Engl J Med, 359, 2008: 2839-2841.
SITS-MOST: Wahlgren N, Ahmed N, D?valos A, Ford G, Grond M, Hacke W, Hennerici M, Kaste M, Kuelkens S, Larrue V. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study. Lancet, 369 (9558), 2009: 275-282.
Tomsick TA, Khatri P, Jovin T, Demaerschalk B, Malisch T, Demchuk A, Hill MD, Jauch E, Spilker J, Broderick JP: Equipoise among recanalization strategies. Neurology. 2010, 74:1069-1076.
T ruelsen R. Cost of Stroke in Europe Eur J Neurol 12, 2005: 78-84.
Wardlaw B, Donnan D, Marcus R. Tissue plasminogen activator in acute ischemic stroke: time for collegiate communication and consensus. Med J Aust 179, 2003: 333-334.
Whisnant J. Changing incidence and mortality rates of stroke. J Stroke, 26, 1995: 924-929.
Email this article (Login required) 
